X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.12−0.05 (-1.58%)
Close on Nov 13, 2026Market cap $309.34MP/E –Yield –
X4 Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
X4 Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$78.61M. For fiscal 2025 it was -$85.61M. The highest annual figure on record is -$22.18M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.61M | – |
| FY2024 | Dec 31, 2024 | -$35.61M | – |
| FY2023 | Dec 31, 2023 | -$107.10M | – |
| FY2022 | Dec 31, 2022 | -$87.06M | – |
| FY2021 | Dec 31, 2021 | -$84.61M | – |
| FY2020 | Dec 31, 2020 | -$59.52M | – |
| FY2019 | Dec 31, 2019 | -$51.60M | – |
| FY2018 | Dec 31, 2018 | -$28.98M | – |
| FY2017 | Dec 31, 2017 | -$22.18M | – |
| FY2016 | Dec 31, 2016 | -$24.06M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$19.66M | – |
| Q2 FY2026 | Jun 30, 2026 | -$15.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.48M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.88M | -136.3% |
| Q1 FY2025 | Mar 31, 2025 | -$8.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$35.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.23M | – |
| Q2 FY2024 | Jun 30, 2024 | $71.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.68M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.87M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.55M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.55M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.03M | -464.4% |
| Q3 FY2018 | Sep 30, 2018 | -$8.52M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.08M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.20M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.60M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.78M | – |
See a number that looks wrong?